Your session is about to expire
← Back to Search
Evorpacept + Cetuximab + Pembrolizumab for Colorectal Cancer
Study Summary
This trial will test a new combo treatment for a particularly stubborn form of colorectal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood and organs are functioning well.My cancer is MSI-high or has mismatch repair deficiency.You have had severe allergic reactions to any of the study medications or similar medications in the past.I have colorectal cancer that has spread and received at least two treatments.I don't know my cancer's mismatch repair or microsatellite status.My cancer is microsatellite stable.I have previously been treated with specific immune therapy drugs.My colorectal cancer is on the left side, has not spread, and I haven't had EGFR inhibitor treatment.
- Group 1: Evorpacept (ALX148) + cetuximab + pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How is ALX148 used to help patients?
"ALX148 is most often used to treat unresectable melanoma. Additionally, this medication can be useful for patients with microsatellite instability high, a high risk of recurrence, and those who cannot tolerate irinotecan."
Is this a unique clinical trial?
"As of now, 1123 clinical trials for ALX148 are ongoing in 65 nations and 3235 cities. The first trial for this medication was conducted back in 2005 by Bristol-Myers Squibb. It completed Phase 2 drug approval after involving 154 patients. Since then, 616 more trials have been concluded."
Has ALX148 been cleared by the FDA for public use?
"While there is some data indicating that ALX148 is safe, as this is only a Phase 2 trial, it scored a 2."
Does the research on ALX148 build upon other scientific literature?
"There are a total of 1123 ongoing clinical trials for ALX148. Of these, 149 are in Phase 3. Most of the trials are being conducted out of Scottsdale, Arizona; however, there are 41336 locations running studies for ALX148."
Are there any current openings for individuals who want to participate in this trial?
"The clinical trial is actively looking for participants and has been doing so since it was originally posted on 8/1/2022. The most recent update to the listing was on 7/28/2022."
How many people are being given this experimental medication?
"Yes, the data hosted on clinicaltrials.gov supports that this trial is currently seeking patients. This particular study was posted on August 1st, 2020 and updated as recently as July 28th, 2020. 80 individuals are needed to enroll at 5 different sites."
In how many different medical care facilities is this clinical trial taking place?
"Currently, this research is taking place in Fairway, New Brunswick, Tucson and 5 additional locations. If you are thinking of participating it might be beneficial to choose the clinical site that is closest to your home to cut down on travel time."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger